CVC  Roche Venture Fund

     Office Locations:

South San Francisco, CA



  • Growth



  • Information Technology
  • Life Sciences & Healthcare



    The Roche Venture Fund is the corporate venture fund of the healthcare company Roche. The fund invests in innovative biotech and diagnostics companies to develop commercially successful life science companies. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. RVF invests globally with a portfolio of over 30 companies in 10 countries. Initial investment ranges from CHF 1-5 million, depending on the stage of the company, the pre-money valuation, and the amount being raised. In general, RVP prefers to be in the 10-15% ownership range. Areas of particular interest to the fund include: oncology, central nervous system, inflammation, virology, in vitro diagnostics,and molecular diagnostics.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Simon Greenwood Investment Director


    Recent Funding Events (trailing 12 months):







      IDEAYA Biosciences



      Series B


      Pandion Therapeutics



      Series A





      Series D


    Portfolio companies include:

        web link

      Afferent Pharmaceuticals
        web link

      Aileron Therapeutics
        web link

      Alios BioPharma
        web link

        web link

      Ambit Biosciences
        web link

        web link

        web link

      C4 Therapeutics
        web link

      Conatus Pharmaceuticals
        web link

        web link

      CytomX Therapeutics
        web link

      DVS Sciences
        web link

      Epic Sciences
        web link

      Flatiron Health
        web link

      Foundation Medicine
        web link

      IDEAYA Biosciences
        web link

      Lumos Pharma
        web link

      Lysosomal Therapeutics
        web link

      Macrolide Pharmaceuticals
        web link

        web link

      Misson Therapeutics
        web link

        web link

      Pandion Therapeutics
        web link

      Purigen Biosystems
        web link

        web link

      Silence Therapeutics
        web link

        web link

        web link

        web link

      Tigenix Living Medicines
        web link

      Tioma Therapeutics
        web link


    Recent News: